MedTrace Logo

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

NCT02716610 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-03-23

No results posted yet for this study

Summary

Pharmacokinetic (PK) and Pharmacodynamic (PD) dose-response investigation of Dance-501 inhaled human insulin

Conditions

Interventions

DRUG

INH 69 U (low)

inhaled human insulin

DRUG

INH 69 U (high)

inhaled human insulin

DRUG

INH 139 U

inhaled human insulin

DRUG

INH 208 U

inhaled human insulin

DRUG

LIS 18 U

subcutaneous insulin lispro

Sponsors & Collaborators

  • Dance Biopharm Inc.

    lead INDUSTRY

Principal Investigators

  • Tim Heise, MD · Profil Institut für Stoffwechselforschung GmbH

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-01-31
Completion
2014-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02716610 on ClinicalTrials.gov